Posted by Michael Wonder on 17 Aug 2018
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
17 August 2018 - NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used by the NHS post surgery to prevent breast cancer recurrence.
The latest draft guidelines do not recommend Perjecta (pertuzumab) for treating early HER2-positive breast cancer after surgery in people who have a high risk of the disease recurring.
The Institute believes further consultation is needed “to give people the opportunity to comment on updated cost-effectiveness estimates”, which take into account the costs of administering the drugs, and the impact of cheaper biosimilar trastuzumab on reducing the overall cost of the adjuvant pertuzumab regimen.
